|Last Price||Today's Change||52-Week Range||Trading Volume|
|68.08||0.26 (+0.38%)||51.82 - 70.54||3.7 million (Below Avg)|
Market data as of 4:01PM 11/25/15. Quotes are delayed by at least 15 min.
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
11/24/2015 6:55 AM ET
Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab), the Only Treatment to Deliver Significant Overall Survival in Advanced Renal Cell Carcinoma vs. a Standard of Care, in Patients Who Have Received Prior Anti-Angiogenic Therapy1
11/23/2015 7:23 PM ET